Fig. 4From: Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysisMeta-analysis of finerenone and GLP1-RA trials on HHF stratified by drug classBack to article page